#China #Guangzhou #Mantle Cell Lymphoma #Rocbrutinib #Lupeng Pharma

Rocbrutinib Approved in China for Lymphoma Treatment

Lupeng Pharmaceutical recently achieved a significant breakthrough in cancer treatment with the accelerated approval of Rocbrutinib (development code LP-168) by China's National Medical Products Administration (NMPA). This fourth-generation Bruton’s tyrosine kinase (BTK) inhibitor is now available for adult patients suffering from relapsed or refractory mantle cell lymphoma (R/R MCL), who have undergone at least two previous systemic therapies, including BTK inhibitors.

Rocbrutinib stands out due to its dual action mechanism—offering both covalent (irreversible) and non-covalent (reversible) binding capabilities. This innovative approach provides a fresh avenue for R/R MCL patients, particularly those who have not responded to earlier-generation BTK inhibitors.

Dr. Tan Fenlai, the co-founder and CEO of Lupeng Pharmaceutical, remarked on this achievement as a pivotal moment in the company’s journey. He highlighted that Rocbrutinib not only offers a promising treatment option for those with persistent MCL but also showcases Lupeng’s commitment to advancements in BTK-targeted therapies.

The approval of Rocbrutinib followed promising results from a comprehensive clinical trial known as the ROCK-1 study, which was conducted across 41 centers in China. This Phase II registration trial yielded an objective response rate (ORR) of 63.9% and a complete response rate (CR) of 23%. Patients involved in the study exhibited severe disease progression prior to participation, underscoring the need for innovative treatment strategies.

From a safety standpoint, the trial reported no incidents of serious cardiac events, including atrial fibrillation or flutter. Importantly, adverse events did not lead any patients to withdraw from the treatment, indicating that Rocbrutinib has a favorable safety profile when administered to this high-risk patient group.

In a further testament to Rocbrutinib's potential, the Chinese Society of Clinical Oncology (CSCO) included it as a Category II recommendation in their treatment guidelines for R/R MCL before formal NMPA approval. This preemptive endorsement points to its innovative mechanism and significant clinical value in filling the treatment gap for patients inadequately served by existing therapies.

Renowned experts like Professor Weiping Liu and Professor Jun Ma have emphasized the difficulties in managing R/R MCL due to the absence of effective standard treatments, presenting a pronounced challenge for healthcare providers. Rocbrutinib’s ability to target resistance mutations on top of its dual-binding mechanism enhances its therapeutic promise.

Looking ahead, Dr. Chen Yi, co-founder and CSO, emphasized that Rocbrutinib’s launch is a success story that exemplifies the company’s innovative development methodology. The approval also paves the way for ongoing clinical studies into other hematological malignancies, including diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

The approach of harnessing novel mechanisms of action in drug development is central to Lupeng Pharmaceutical's mission. As Rocbrutinib gains traction in the treatment of R/R MCL, its efficacy is also being evaluated for other B-cell malignancies, which is expected to catalyze the drug's market penetration and further validation of its clinical utility.

In summary, Rocbrutinib's approval marks a transformative step in the treatment landscape for mantle cell lymphoma in China, potentially leading to improved outcomes for countless patients battling this challenging disease. With its innovative formulation and the backing of clinical evidence, Rocbrutinib is set to be a cornerstone in future therapeutic regimens for hematologic malignancies.